ID: h-SDA-2026-04-26-gap-debate-20260417-033
Hypothesis
Axonal Integrity Recovery Following Amyloid Clearance Drives CSF p-tau217 Normalization
Donanemab treatment reduces amyloid-induced axonal transport deficits and endosomal trafficking impairment.
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
Donanemab treatment reduces amyloid-induced axonal transport deficits and endosomal trafficking impairment. Restored axonal integrity decreases the release of tau fragments and hyperphosphorylated tau species into CSF. However, this hypothesis conflates intracellular tau phosphorylation with extracellular tau release, and the primary source of CSF tau (extracellular release mechanisms including unconventional secretion, synaptic activity-dependent release, and necrotic cell death) is not adequately addressed by axonal transport mechanisms.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Amyloid Clearance<br/>Therapeutic Intervention"]
B["Axonal Integrity<br/>Recovery Signal"]
C["RAB GTPase Activity<br/>Axonal Transport Restoration"]
D["MAPT/Tau Function<br/>Microtubule Stabilization"]
E["CSF p-tau217<br/>Normalization"]
F["Neuronal Health<br/>Restored"]
G["Biomarker-Linked<br/>Mechanistic Validation"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"confirms"| D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix3 supports4 contradicts
Supports
Aβ oligomers impair axonal transport through tau hyperphosphorylation-dependent mechanisms
Supports
Amyloid immunotherapy restores neuronal connectivity and reduces phospho-tau immunoreactivity
Supports
CSF neurofilament light chain (NfL) declines with successful amyloid removal, supporting axonal recovery
Contradicts
Axonal integrity recovery (NfL decline) takes 12-18 months while p-tau217 changes are detectable at 6-12 months; temporal mismatch undermines mechanism
Contradicts
NfL decline is not strongly correlated with p-tau217 decline in clinical trials, suggesting independent mechanisms
Contradicts
CSF tau is primarily derived from extracellular tau release, not axonal transport of phosphorylated tau
Contradicts
Tau release mechanisms include unconventional secretion pathways and synaptic activity-dependent release—not primarily axonal transport deficits
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MAPT
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for MAPT, RAB GTPases from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MAPT, RAB GTPases.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.2453
Events (7d)
1
Price History
▲9.5%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF Donanemab treatment achieves ≥50% reduction in amyloid plaque burden (Centiloid <20) THEN CSF p-tau217 concentrations will decrease by ≥40% within 12 months post-baseline, with the temporal traject | CSF p-tau217 levels will show ≥40% reduction at 12 months, and the magnitude/timing of this reduction will correlate (r > 0.5) with concurrent NfL reduction | — no observation — | pending | 0.60 |
| IF patients are stratified at baseline by elevated CSF tau release markers (extracellular/extracellular vesicle-associated tau) versus primarily axonal damage markers THEN those with dominant axonal t | High axonal-damage/low extracellular-tau subgroup will exhibit ≥50% greater CSF p-tau217 reduction compared to high extracellular-tau subgroup | — no observation — | pending | 0.40 |
🔮 Falsifiable Predictions (2)
pendingconf 60%
IF Donanemab treatment achieves ≥50% reduction in amyloid plaque burden (Centiloid <20) THEN CSF p-tau217 concentrations will decrease by ≥40% within 12 months post-baseline, with the temporal trajectory of CSF p-tau217 decline positively correlating with the rate of axonal integrity recovery as mea
Predicted outcome: CSF p-tau217 levels will show ≥40% reduction at 12 months, and the magnitude/timing of this reduction will correlate (r > 0.5) with concurrent NfL red
Falsification: CSF p-tau217 remains unchanged or increases despite confirmed amyloid clearance and measurable axonal integrity recovery (decreasing NfL); or CSF p-tau217 declines independently of axonal integrity ma
pendingconf 40%
IF patients are stratified at baseline by elevated CSF tau release markers (extracellular/extracellular vesicle-associated tau) versus primarily axonal damage markers THEN those with dominant axonal transport deficits (high CSF NfL, low extracellular vesicle tau) will show significantly greater CSF
Predicted outcome: High axonal-damage/low extracellular-tau subgroup will exhibit ≥50% greater CSF p-tau217 reduction compared to high extracellular-tau subgroup
Falsification: No significant difference in CSF p-tau217 response between axonal-dominant and extracellular-release-dominant subgroups, indicating amyloid clearance reduces extracellular tau independently of axonal
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.